SCHEMBL4173630

SCHEMBL4173630

Cc1nc(-c2cccnc2)sc1-c1ccnc(Nc2ccc(N3CCOCC3)c(Cl)c2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 11/20 0.55
CDK4 P11802 5/20 0.55
AURKA O14965 4/20 0.55
AURKB Q96GD4 4/20 0.55
CDK9 P50750 8/20 0.55
CDK1 P06493 5/20 0.55
CCNT1 O60563 6/20 0.54
ACVR1 Q04771 3/20 0.54
ABL1 P00519 3/20 0.54
CAMK2D Q13557 2/20 0.54
BCR P11274 2/20 0.54
JAK2 O60674 2/20 0.54
MAPK8 P45983 2/20 0.54
MAPK10 P53779 2/20 0.54
CDC7 O00311 1/20 0.54
PLK4 O00444 1/20 0.54
CIT O14578 1/20 0.54
CHEK1 O14757 1/20 0.54
GAK O14976 1/20 0.54
EPHB6 O15197 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160392 0.91 CDK2 (0.59) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4170629 0.90 IGF1R (0.53) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4173509 0.88 CDK2 (0.71) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4176583 0.85 CDK2 (0.75) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4166920 0.84 CDK2 (0.58) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4164547 0.84 ACVR1 (0.53) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4159171 0.82 CDK2 (0.77) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4176513 0.81 CDK2 (0.60) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4164507 0.80 CDK4 (0.52) CDK2CDK4AURKAAURKBCDK9
SCHEMBL4160087 0.79 CDK2 (0.71) CDK2CDK4AURKAAURKBCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 CDK2 1/4885CDK4 2/4885AURKA 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.